Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Allogene Therapeutics, Inc. has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 3 distinct examiners across 2 distinct art units. ZHU, JIANJIAN is the busiest examiner with 2 pending actions. This individual handles a portion of the 4 pending office actions for the company.
The distribution of cases across 3 distinct examiners ensures that the company receives multiple perspectives within the Biotechnology & Pharmaceuticals sector. ZHU, JIANJIAN manages 2 pending actions, making his examination style a significant factor in the current prosecution. The 2 distinct art units provide technical grouping for the 4 pending office actions. Practitioners should focus on the specific nuances of each assigned examiner, particularly the one handling multiple cases. This structure ensures that the company's success is not entirely tied to a specific person. Every development in the 3 distinct examiners' work is important for the portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHU, JIANJIAN | 2 | 58.8% | +82.4% |
| WENG, KAI H | 1 | 70.2% | +17.2% |
| MIANO, JOSEPH PAUL | 1 | 36.0% | +63.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17010707 | METHODS OF PREPARING T CELLS FOR T CELL THERAPY | MIANO, JOSEPH PAUL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17064241 | Plastic Jacket for Vial Labeling Systems | WENG, KAI H | 15d |
| 17841041 | SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE | ZHU, JIANJIAN | 76d |
| 19353269 | SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE | ZHU, JIANJIAN | — |
| 17010707 | METHODS OF PREPARING T CELLS FOR T CELL THERAPY | MIANO, JOSEPH PAUL | — |
| Art Unit | Apps |
|---|---|
| 1631 | 3 |
| 3781 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19353269 | SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE | ZHU, JIANJIAN | 1631 | §103§112DP | Non-Final OA | — | Pending | Oct 08, 2025 |
| 17841041 | SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE | ZHU, JIANJIAN | 1631 | §103§112DPOther | Final Rejection | 76d | Pending | Jun 15, 2022 |
| 17064241 | Plastic Jacket for Vial Labeling Systems | WENG, KAI H | 3781 | §103 | Final Rejection | 15d | Pending | Oct 06, 2020 |
| 17010707 | METHODS OF PREPARING T CELLS FOR T CELL THERAPY | MIANO, JOSEPH PAUL | 1631 | §101§103§112 | Non-Final OA | — | Pending | Sep 02, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial